Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project

Share Name	Share Symbol	Market	Type
Transgene S.A. ADS (MM)	NASDAQ:TRGNY	NASDAQ	Ordinary Share

Transgene . (NASDAQ:TRGNY)
Historical Stock Chart

From Jun 2019 to Jun 2024

Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project STRASBOURG, France, July 1 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced that it manufactured clinical lots of HIV vaccine candidates in the frame of EUROVAC (European Vaccine Effort against HIV/AIDS), a European cluster of 21 laboratories, funded since 2000 by the European Union under the 5th Framework Programme. Partners of EUROVAC, the Karolinska Institutet and Aventis Pasteur, recognizing Transgene's know-how in the field of recombinant vaccines production, selected the company to produce clinical lots of NYVAC-based vaccines carrying genes of HIV-1. Production was completed in Transgene's manufacturing facility located near Strasbourg, through adaptation of its own MVA manufacturing process to the production of NYVAC-based products. NYVAC and MVA are both attenuated strains of the vaccinia virus. "We are very proud of the confidence put in us by the Karolinska Institutet, EUROVAC and Aventis Pasteur for our manufacturing capabilities of recombinant vaccines," stated Jean-Francois Carmier, Chief Executive Officer of Transgene. "We believe manufacturing contracts add value to our expertise, while contributing to reducing our burn rate." About Transgene Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines, immunotherapy products, and delivery technologies for the treatment of diseases for which there is no cure or adequate treatment at present, with a focus on the treatment of cancer. Transgene has five products in clinical development, two of which are in Phase II clinical trials, two in Phase I/II and one that has completed Phase I clinical trial. Transgene's proprietary vector technology platform consists of adenovirus and poxvirus. This press release contains forward-looking statements, including statements regarding Transgene manufacturing capabilities. Statements that are not historical facts are based on Transgene's current expectations, beliefs, estimates, forecasts and assumptions, including Transgene's expectations related to the reproducibility in humans of the preclinical results, progress in the clinical trials and Transgene's belief as to the potential to successfully manufacture products for the effective treatment of illness. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict. Accordingly, actual outcomes and results may differ materially from what is expressed in those forward-looking statements. Important factors which may affect Transgene's future operating results include the following: Transgene's product candidates may not demonstrate therapeutic efficacy after initial promising results, Transgene may be unable to obtain regulatory approval for its product candidates, Transgene may be unable to conduct its clinical trials as quickly as it has predicted, Transgene's clinical trials may not produce results sufficient to justify further product development, Transgene may not have sufficient resources to complete the research, manufacturing and commercialization of any of its product candidates, competitors may develop technologies or products superior to Transgene's technologies or products, Transgene may not be able to successfully enforce the intellectual property rights in all jurisdictions relating to its product candidates and other important factors described in Transgene's Annual Report on Form 20-F for the year ended December 31, 2003 filed with the U.S. Securities and Exchange Commission, including those factors described in the section entitled "Risk Factors." DATASOURCE: Transgene CONTACT: Michel Hubert, VP Business Development, Transgene, +33-3-88-27-91-12; Michael Long, Cohn & Wolfe, +1-212-798-9775; Estelle Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn, +33-1-53-70-74-64, both of Image 7, for Transgene

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

TRGNY Transgene S.A. ADS (MM)